Skip to main content
Premium Trial:

Request an Annual Quote

Pharma Consortium Taps BioFortis Software for Biobanking, Clinical Data Management

Premium

BioFortis said this week that the Progressive Multifocal Leukoencephalopathy Consortium, a not-for-profit pharmaceutical collaboration, has selected its Labmatrix and Qiagram software programs to share and manage biospecimen data.

According to BioFortis, researchers in the PML Consortium will use its software to centrally manage de-identified patient clinical profiles and biospecimen information stored in a virtual sample bank; analyze available samples and associated data; request, approve, and track transfers of the samples; and log user interactions and virtual sample bank inventory history.

The PML consortium — which includes Biogen-Idec, Elan, Bristol-Myers Squibb, Pfizer, and Roche — was set up to pool study resources related to progressive multifocal leukoencephalopathy, an often fatal disease in immunocompromised patients that is caused by the John Cunningham virus. The pooled approach is expected to help the researchers derive insights that might not be gained from individual studies.

The group's goal is to reduce the occurrence, morbidity, and mortality of PML using a collaborative approach to data collection, research and analysis, and communication.

Sophie Banzet, who chairs the consortium's board of directors, said in a statement that the BioFortis tools will enable its members to conduct research into PML and its causes in a "collaborative" fashion.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.